Jupiter Neurosciences Announces First Patient Dosed in Phase 2a RESET Trial in Parkinson’s Disease and Exploration of Strategic Options to Maximize Shareholder Value
Jupiter Neurosciences dosed the first patient in its Phase 2a RESET trial (NCT07592767) evaluating JOTROL, its micellar trans-resveratrol formulation, in Parkinson's disease. The multicenter, randomized, placebo-controlled study will enroll roughly 30 patients treated orally for 12 weeks, assessing safety, pharmacokinetics and biomarkers. Simultaneously, Jupiter has retained Tungsten Advisors to explore strategic options — including asset sales, licensing, partnerships or a business combination — to maximize shareholder value, with no assurance of any transaction. Georgetown University is the study sponsor; the Parkinson's franchise addresses an estimated 1.1 million U.S.
Key figures
- Drug Name
- JOTROL (micellar trans-resveratrol)
- Phase Of Trial
- Phase 2a
- Trial name
- RESET
- Randomization
- 1:1:1 to two JOTROL dose levels or placebo
- Trial identifier
- NCT07592767
- Planned enrollment
- approximately 30 patients
- Treatment duration
- 12 weeks
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.